Omeros Corporation (OMER)
8.21
-0.20 (-2.38%)
At close: Mar 03, 2025, 3:59 PM
8.15
-0.73%
After-hours: Mar 03, 2025, 06:33 PM EST
No 1D chart data available
| Bid | 8 |
| Market Cap | 475.77M |
| Revenue (ttm) | 1.37M |
| Net Income (ttm) | -134.53M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -2.61 |
| Forward PE | -4.9 |
| Analyst | Hold |
| Ask | 8.5 |
| Volume | 444,340 |
| Avg. Volume (20D) | 724,420 |
| Open | 8.40 |
| Previous Close | 8.41 |
| Day's Range | 8.09 - 8.47 |
| 52-Week Range | 2.61 - 13.60 |
| Beta | 1.98 |
About OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell tr...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2009
Employees 198
Stock Exchange NASDAQ
Ticker Symbol OMER
Website https://www.omeros.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $22.5, which is an increase of 174.06% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
1 week ago
+3.89%
Omeros shares are trading after the company announ...
Unlock content with
Pro Subscription
2 months ago
+37.27%
Omeros shares are trading higher after the company announced that narsoplimab met its primary trial endpoint and will resubmit its narsoplimab Biologics License Application to the FDA.
